JP2010530362A5 - - Google Patents

Download PDF

Info

Publication number
JP2010530362A5
JP2010530362A5 JP2010510239A JP2010510239A JP2010530362A5 JP 2010530362 A5 JP2010530362 A5 JP 2010530362A5 JP 2010510239 A JP2010510239 A JP 2010510239A JP 2010510239 A JP2010510239 A JP 2010510239A JP 2010530362 A5 JP2010530362 A5 JP 2010530362A5
Authority
JP
Japan
Prior art keywords
hpv
amino acid
derived
protein
medicament
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010510239A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010530362A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/NL2008/050315 external-priority patent/WO2009002159A2/en
Publication of JP2010530362A publication Critical patent/JP2010530362A/ja
Publication of JP2010530362A5 publication Critical patent/JP2010530362A5/ja
Pending legal-status Critical Current

Links

JP2010510239A 2007-05-31 2008-05-27 皮内hpvペプチドワクチン接種 Pending JP2010530362A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94107007P 2007-05-31 2007-05-31
EP07109287 2007-05-31
PCT/NL2008/050315 WO2009002159A2 (en) 2007-05-31 2008-05-27 Intradermal hpv peptide vaccination

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014133168A Division JP5888823B2 (ja) 2007-05-31 2014-06-27 皮内hpvペプチドワクチン接種

Publications (2)

Publication Number Publication Date
JP2010530362A JP2010530362A (ja) 2010-09-09
JP2010530362A5 true JP2010530362A5 (enExample) 2011-06-30

Family

ID=38477016

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010510239A Pending JP2010530362A (ja) 2007-05-31 2008-05-27 皮内hpvペプチドワクチン接種
JP2014133168A Expired - Fee Related JP5888823B2 (ja) 2007-05-31 2014-06-27 皮内hpvペプチドワクチン接種

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014133168A Expired - Fee Related JP5888823B2 (ja) 2007-05-31 2014-06-27 皮内hpvペプチドワクチン接種

Country Status (10)

Country Link
US (2) US9562075B2 (enExample)
EP (1) EP2155240B1 (enExample)
JP (2) JP2010530362A (enExample)
CN (1) CN101795705A (enExample)
AU (1) AU2008269721B2 (enExample)
BR (1) BRPI0812311A8 (enExample)
CA (1) CA2688589A1 (enExample)
ES (1) ES2482192T3 (enExample)
MX (1) MX2009012922A (enExample)
WO (1) WO2009002159A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008257792B2 (en) * 2007-05-31 2013-08-29 Isa Pharmaceuticals B.V. HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines
EP2344191A4 (en) * 2008-09-02 2013-02-13 Antigen Express Inc HUMAN PAPILLOMAVIRUS / LI-KEY HYBRIDS AND METHODS OF USE
CA2819416C (en) 2010-12-02 2019-04-30 Bionor Immuno As Peptide scaffold design
EP2883550A1 (en) * 2013-12-12 2015-06-17 Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts Novel promiscuous HPV16-derived T helper epitopes for immunotherapy
US10934525B2 (en) 2015-10-30 2021-03-02 Children's National Medical Center Generating HPV antigen-specific cells from a naive T cell population
EP3377099A4 (en) 2015-11-18 2019-07-24 ImmunoVaccine Technologies Inc. ADJUVANT SYSTEMS AND WATER-FREE VAPOR COMPOSITION OF ONE POLYI: C-POLYNUCLEOTIDADJUVANS AND ADJUVANS ON LIPID BASE
MY201964A (en) * 2016-06-20 2024-03-27 Isa Pharmaceuticals B V Formulation of a peptide vaccine
WO2019099723A2 (en) * 2017-11-15 2019-05-23 Arizona Board Of Regents On Behalf Of Arizona State University Materials and methods relating to immunogenic epitopes from human papillomavirus
JP7595827B2 (ja) * 2018-03-12 2024-12-09 ステムセル テクノロジーズ カナダ インコーポレーテッド 免疫応答を改変するための生体分子の細胞内送達
PE20201201A1 (es) * 2018-03-12 2020-11-11 Sqz Biotechnologies Co Metodos para tratar las enfermedades asociadas al vph
WO2019210055A2 (en) * 2018-04-26 2019-10-31 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
WO2022147442A1 (en) * 2020-12-29 2022-07-07 Sqz Biotechnologies Company Formulations of activating antigen carriers

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
US5180806A (en) * 1988-05-16 1993-01-19 The Scripps Research Institute Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods
US5932412A (en) 1990-05-11 1999-08-03 Euro-Diagnostica Ab Synthetic peptides in human papillomaviruses 1, 5, 6, 8, 11, 16, 18, 31, 33 and 56, useful in immunoassay for diagnostic purposes
DE9106105U1 (de) * 1991-05-17 1991-09-26 Behringwerke Ag, 3550 Marburg Diagnose-Kit zum Nachweis von Human-Papillomavirusinfektionen
US6419931B1 (en) 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
GB9505784D0 (en) * 1995-03-22 1995-05-10 Lynxvale Ltd Anti-tumour treatment
AU721927B2 (en) 1995-12-22 2000-07-20 Immunomedics Inc. Use of immunoconjugates to enhance the efficacy of multi-stage cascade boosting vaccines
ES2330017T3 (es) 1998-05-23 2009-12-03 Leiden University Medical Center Ligandos de cd40 y peptidos de ctl para tratar tumores.
US20030118588A1 (en) 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
US6641994B2 (en) * 1999-08-25 2003-11-04 Pharmacia & Upjohn Company Methods of identifying anti-viral agents
US20020044948A1 (en) * 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
ES2519043T3 (es) * 2000-12-08 2014-11-06 Academisch Ziekenhuis Leiden Péptidos largos de 22-45 residuos de aminoácidos que inducen y/o mejoran las respuestas inmunológicas específicas para antígenos
WO2003008649A1 (en) * 2001-07-20 2003-01-30 Board Of Regents, The University Of Texas System Methods and compositions relating to hpv-associated pre-cancerous and cancerous growths, including cin
US6884605B2 (en) * 2001-08-09 2005-04-26 Board Of Trustees Of The University Of Arkansas Compositions, methods and products comprising human papillomavirus for detecting and treating a cancer
AU2004308964B2 (en) 2003-12-23 2010-09-16 Arbor Vita Corporation Antibodies for oncogenic strains of HPV and methods of their use
EP1699479A1 (en) * 2003-12-24 2006-09-13 Leiden University Medical Center Synthetic protein as tumor-specific vaccine
US8252893B2 (en) 2005-01-31 2012-08-28 Board Of Trustees Of The University Of Arkansas CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof
DE602006021408D1 (de) * 2005-04-27 2011-06-01 Univ Leiden Medical Ct Behandlung von hpv-induzierter intraepithelialer anogenitaler neoplasien
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante

Similar Documents

Publication Publication Date Title
JP2010530362A5 (enExample)
Wu et al. Improving therapeutic HPV peptide-based vaccine potency by enhancing CD4+ T help and dendritic cell activation
CN101528255A (zh) Hpv抗原融合蛋白疫苗组合物及其应用
JP6811014B2 (ja) B型肝炎ウイルスに対するワクチン
WO2004003143A3 (en) Viruses and virus-like particles for multiple antigen and target display
CN1678344A (zh) 人乳头状瘤病毒治疗
WO2003090686A3 (en) Using heat shock proteins to improve the therapeutic benefit of a non-vaccine treatment modality
US10233215B2 (en) Peptide and use thereof
JP2013542224A5 (enExample)
RU2011123700A (ru) Нонапептид с противоопухолевой активностью
Chuang et al. Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination
JP2014508734A5 (enExample)
RU2012136530A (ru) Новые соединения, влияющие на пищевое поведение
KR20200027956A (ko) 키메라 바이러스-유사 입자 및 면역 반응의 항원-특이적 재지향자로서의 이의 용도
EP1699479A1 (en) Synthetic protein as tumor-specific vaccine
JP2022172244A5 (enExample)
JP2011529475A5 (enExample)
US8470372B2 (en) Material with immunogenicity
Torréns et al. Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing tumors
JP2009538836A (ja) 生物活性の精製HspE7組成物
WO2017177908A1 (zh) Pd-l1和pd-l2重组蛋白及其用途
WO2017177907A1 (zh) 抗免疫检查点pd-l1和pd-l2肿瘤疫苗
KR100904844B1 (ko) 인유두종 바이러스(hpv)유전자를 포함하는자궁경부암의 치료 또는 예방용 dna 백신
CN103119168A (zh) 人乳头瘤病毒e7抗原组合物及其用途
KR20180112043A (ko) 백신을 사용하여 암 또는 피부 병변을 치료하기 위한 방법 및 조성물